Co-diagnostics, Inc. · NASDAQ:CODX
Co-diagnostics — Investor Presentation (2026)
16 slides from Co-diagnostics's investor presentation, 2026
Slide 1: Co-Dx
Slide 2: Forward Looking Statement
Forward Looking Statement THESE MATERIALS CONTAIN FORWARD-LOOKING STATEMENTS THAT INVOLVE SIGNIFICANT RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPECTED. THERE CAN BE NO ASSURANCE THAT ANY ANTICIPATED RESULTS WILL OCCUR ON A TIMELY BASIS OR AT ALL, DUE
Slide 3: Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not
Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.
Slide 4: Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not
Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.
Slide 5: Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not
REF Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.
Slide 6: Ebola Response
Ebola Response Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.
Slide 7: Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not
Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.
Slide 8: Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not
Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.
Slide 9: Slide 9
Slide 10: Slide 10
Slide 11: CoSara Pvt. Ltd
Slide 12: India Region-Market Size
India Region-Market Size Diagnostic Market Size Estimates $11.4B Current estimated _ diagnostic market size e for the India regi g e or the India region & n s e S = Nee lladesh inglades! $1.68 ¢ L-] $134.0M $49.9M $40.1M 4 = =a India Bangladesh Pakistan Sri Lanka Nepal ~4.9 trillion 8.5% Expanding s
Slide 13: Sources: Molbio Diagnostics IPO filings and company disclosures, 2026
Sources: Molbio Diagnostics IPO filings and company disclosures, 2026. ® Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.
Slide 14: MTB Clinical Studies
iwi | MTB Clinical Studies Validating the complete decentralized MTB workflow in one of the world’s highest-burden TB markets. 1. SAMPLE 2. LYSIS 3. PCR PRO 4. MTB RESULT Swabbed sputum or tongue Heat-kill sample prep Multiplex real-time PCR On mobile app and cloud Sco ie ag gS ~ = sd \-- Sie SS CLI
Slide 15: India Update: Building capability
INDIA UPDATE Building capability. Expanding in-house capabilities that strengthen PCR Pro® and create commercial opportunities. IN-HOUSE MASTER MIX AND EXTRACTION KIT OLIGONUCLEOTIDE PRODUCTION SAMPLE PREPARATION Supporting CoSara assays with In-house synthesis for CoSara assays A dedicated lysis pl
Slide 16: Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not
Confidential & Proprietary. This document is the property of Co-Diagnostics, Inc. and may not be shared, copied, or distributed without written permission.